Actualités Osmotica Pharmaceuticals PLC - OSMT | Actions NASDAQ

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales Guidance

-- Fourth Quarter 2021 net sales for UPNEEQ grew by approximately 41% to $3.1 million compared to the third...

Current Report Filing (8-k)

0001739426 false 12/31 Osmotica Pharmaceuticals plc 00-0000000 0001739426 2022-01-14 2022-01-14 iso4217:USD xbrli:shares iso4217:USD...

RVL Pharmaceuticals to Host UPNEEQ® Overview and Business Update Webcast on January 19, 2022

-- Topics include corporate name change, launch plans into the medical aesthetics market and general business...

Osmotica Pharmaceuticals plc to Host UPNEEQ® Overview and Business Update Call on January 19, 2022

BRIDGEWATER, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica”...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Osmotica Pharmaceuticals plc to Present at H.C. Wainwright Bioconnect Conference

BRIDGEWATER, N.J., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica”...

Proxy Statement (definitive) (def 14a)

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...

Securities Registration: Employee Benefit Plan (s-8)

As filed with the Securities and Exchange Commission on November 16, 2021 REGISTRATION NO. 333...

Current Report Filing (8-k)

0001739426 false 00-0000000 0001739426 2021-11-15 2021-11-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares ...

Quarterly Report (10-q)

0.130.160.290.2100000000-000000062545832631272880.420.031.010.620.280.140.720.410P5Y--12-312021Q30001739426false0001739426osmt:ReserveForCo...

Osmotica Pharmaceuticals plc Reports Third Quarter 2021 Results and Provides Business Update

Third quarter Upneeq® product sales of $2.2 million, representing 47% growth over second quarter sales...

Osmotica Pharmaceuticals plc to Present at Jefferies London Virtual Healthcare Conference 2021

BRIDGEWATER, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica”...

Osmotica Pharmaceuticals plc to Provide Third Quarter 2021 Business and Financial Update on November 15, 2021

BRIDGEWATER, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica”...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Osmotica Pharmaceuticals PLC (OSMT)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

OSMT Actualités

Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales Guidance

Current Report Filing (8-k)

RVL Pharmaceuticals to Host UPNEEQ® Overview and Business Update Webcast on January 19, 2022

Osmotica Pharmaceuticals plc to Host UPNEEQ® Overview and Business Update Call on January 19, 2022

Statement of Changes in Beneficial Ownership (4)

Osmotica Pharmaceuticals plc to Present at H.C. Wainwright Bioconnect Conference

Proxy Statement (definitive) (def 14a)

Securities Registration: Employee Benefit Plan (s-8)

Current Report Filing (8-k)

Quarterly Report (10-q)

Osmotica Pharmaceuticals plc Reports Third Quarter 2021 Results and Provides Business Update

Osmotica Pharmaceuticals plc to Present at Jefferies London Virtual Healthcare Conference 2021

Osmotica Pharmaceuticals plc to Provide Third Quarter 2021 Business and Financial Update on November 15, 2021

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Osmotica Pharmaceuticals PLC (OSMT) Actualités

Osmotica Pharmaceuticals PLC (OSMT)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

OSMT Actualités

Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales Guidance

Current Report Filing (8-k)

RVL Pharmaceuticals to Host UPNEEQ® Overview and Business Update Webcast on January 19, 2022

Osmotica Pharmaceuticals plc to Host UPNEEQ® Overview and Business Update Call on January 19, 2022

Statement of Changes in Beneficial Ownership (4)

Osmotica Pharmaceuticals plc to Present at H.C. Wainwright Bioconnect Conference

Proxy Statement (definitive) (def 14a)

Securities Registration: Employee Benefit Plan (s-8)

Current Report Filing (8-k)

Quarterly Report (10-q)

Osmotica Pharmaceuticals plc Reports Third Quarter 2021 Results and Provides Business Update

Osmotica Pharmaceuticals plc to Present at Jefferies London Virtual Healthcare Conference 2021

Osmotica Pharmaceuticals plc to Provide Third Quarter 2021 Business and Financial Update on November 15, 2021

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application